Glasgow-based EnteroBiotix secures £27M funding for groundbreaking microbiome therapeutics

The biotechnology firm based in Glasgow has successfully completed a funding round, raising £27 million. This considerable financial boost, supported by a mix of new and existing investors, represents a major achievement for the company as it aims to revolutionise the field of microbiome therapeutics.

The funding round was made up of £15.7m in equity funding, as well as the conversion of £11.6m in loan notes into equity. 

The round saw contributions from seasoned life science investors Thairm Bio and Kineticos Life Sciences, alongside the Scottish National Investment Bank (SNIB). Additionally, existing investors such as Scottish Enterprise and several private investors reaffirmed their commitment.

At the forefront of EnteroBiotix’s agenda with the new funding is the advancement of its lead product candidate, EBX-102-02, through a Phase 2 clinical trial targeting Irritable Bowel Syndrome (IBS) in collaboration with the Functional Gut Clinic. 

Beyond IBS, the company aims to expand its pipeline to address other conditions associated with disruptions in the gut microbiome, including liver cirrhosis and hepatic encephalopathy (HE).

“This significant new investment helps enable our vision of transforming the standard of care for patients suffering from serious conditions linked to the gut microbiome. It will help accelerate the development of our innovative product pipeline and propels us towards our goal of bringing these innovative treatments to market,” said Dr James McIlroy, CEO of EnteroBiotix.

“We look forward to working closely with our new partners at the Bank and with our existing investors to bring this vision to fruition, for the benefit of patients across the globe.”

EnteroBiotix’s endeavours could impact the medical landscape, offering hope for improved treatments and outcomes for patients grappling with gastrointestinal disorders and associated complications. 

According to Statista, the share of adults diagnosed with gastrointestinal conditions in the US is about 22%, a number which jumps to 44% when self reporting.